alzheimer's semaglutide does not slow the progression of disease Tirzepatide: a novel therapeutic approach

Average: 1 to 2 percent body weight loss (2 to 5 pounds for most starting weights)

Currently, there are three FDA-approved semaglutide products: Ozempic, Wegovy, and Rybelsus

However, one study showed that while both of these drugs affect gastric emptying to a similar degree, these effects are much longer lasting with tirzepatide

Because Ozempic helps people eat less, a halt to treatment may lead them to consume more calories and eat larger portions, leading to an increase in blood sugar, Tchang says

Its important to note that this is not a change we are seeing in people who are taking the drug for weight loss purposes

doi: 10.1210/jc.2018-00070 28 MarsoSPBainSCConsoliAEliaschewitzFGJodarELeiterLAet al